= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Collier

MSACL 2018 EU Abstract

Topic: Practical Training

Podium Presentation in the Ether on Wednesday at 9:00 (Chair: Tim Collier)

Proteomic Assay Development: Digest Optimization and Quality Control

Timothy Collier (Presenter)
Quest Diagnostics - Cleveland HeartLab

Presenter Bio(s): Bachelor Degree in Chemistry obtained from NC State University in Raleigh, North Carolina.

Continued Graduate School at NC State with a focus in Bioanalytical Chemistry and a Graduate Minor in Biotechnology under the mentorship of Dr. David Muddiman at the W. M. Keck FT-ICR Mass Spectrometry Laboratory, working on biological systems ranging from fungal crop pathogens to human embryonic stem cell biology, with methodological focuses on quantitative Top-Down and Bottom-Up Proteomic Methodologies.

After completion of Ph.D. 2010, continued as a Post-Doctoral Research Scholar in the division of Molecular Oncology at Washington University School of Medicine in St. Louis, MO, in the lab of Dr. Ron Bose, and with additional mentorship from Dr. Michael Gross, using quantitative and structural proteomics in breast cancer studies focusing on drug resistance and mutation-driven structural effects

Authors: Timothy S. Collier
Quest Diagnostics - Cleveland HeartLab

Abstract

The development of protein mass spectrometric assays for use in the clinical laboratory presents unique workflow challenges. Specific pre-analytical steps, such as enzymatic proteolytic digestion, are often required to generate peptides amenable to mass spectrometric analysis. This process requires close attention during and after assay development to ensure reproducible and accurate clinical analysis.

This practical training session will focus on Digest Optimization, including enzyme selection, reagent systems to boost efficiency, and quality control mechanisms to allow monitoring of digest performance. Additional quality control mechanisms to monitor assay performance will also be discussed, including secondary peptide and ion-ratio monitoring, enrichment process monitoring, and steps to ensure reagent quality.


Financial Disclosure

DescriptionY/NSource
Grantsno
SalaryyesQuest Diagnostics - Cleveland HeartLab
Board Memberno
Stockyes Quest Diagnostics
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no